InVivo Therapeutics

InVivo Therapeutics realigns R&D strategy

Wednesday, June 25, 2014 01:54 PM

As a result of an in-depth review of the company's R&D portfolio, InVivo Therapeutics is realigning resources behind its novel Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells program for spinal cord injury (SCI).

More... »


InVivo opens new office and labs in Cambridge, Mass.

Wednesday, September 26, 2012 10:47 AM

InVivo Therapeutics Holdings (NVIV), a developer of technologies for the treatment of spinal cord injuries and neurotrauma, has opened the company’s new office, manufacturing and lab space at in Cambridge, Mass. Consolidating all of InVivo’s operations, the 21,000 square foot facility will serve as the new headquarters for the company.

More... »


InVivo Therapeutics and The Miami Project to Cure Paralysis form strategic research collaboration

Thursday, May 5, 2011 11:45 AM

InVivo Therapeutics, a company focused on the development of technologies for the treatment of spinal cord injuries (SCI), and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, a spinal cord injury research center, have entered into a strategic research collaboration for the development of novel SCI treatments.

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs